Key Facts About Mesothelioma
Knowing key mesothelioma statistics can help you better understand this rare disease, make more educated decisions about your health and help spread awareness.
- Mesothelioma is caused by exposure to asbestos.
- It accounts for less than 0.3% of all cancer diagnoses in the country.
- There are four types of mesothelioma: Pleural, peritoneal, pericardial and testicular. Pleural is the most common type, representing about 75% of all mesothelioma cases.
- Out of all people with heavy, prolonged exposure to asbestos, 2% to 10% develop pleural mesothelioma.
- Symptoms of mesothelioma usually do not show until 20-50 years after asbestos exposure, which is when tumors have grown and spread.
- The average life expectancy for mesothelioma patients is 12 to 22 months.
Who Gets Mesothelioma?
The typical mesothelioma patient is a man older than 65 with a blue-collar or military background. However, anyone with a history of asbestos exposure is at risk.
Occupations with Greatest Risk of Asbestos Exposure
- Chemical refining
- Power generation
- Military service
Demographic Factors in Mesothelioma Incidence
Mesothelioma incidence describes the risk of getting mesothelioma cancer. Because men are exposed to asbestos more often, they are 4.6 times more likely to be diagnosed with mesothelioma. Of all diagnosed patients, more than 90% are white. Hispanics are diagnosed more frequently than blacks or Asians.
Mesothelioma Incidence by Gender
Mesothelioma Incidence by Race/Ethnicity
Latency Period of Mesothelioma
The gap between the first exposure to asbestos and the appearance of symptoms is called the latency period. Mesothelioma symptoms typically appear 20 to 50 years after exposure to asbestos.
Average Latency Periods by Mesothelioma Type
- Pleural Mesothelioma: 30 to 60 years
- Peritoneal Mesothelioma: 20 to 40 years
Mortality & Survival Rates of Mesothelioma
Mesothelioma is a complex disease, and few doctors have experience diagnosing and treating it. Mesothelioma specialists offer patients the greatest hope.
Death Toll of Mesothelioma
- From 1999 to 2015, a total of 45,221 Americans died from mesothelioma.
- Nearly 80% of those deaths occurred among men.
- About 37% of deaths were people ages 75 to 84.
Mesothelioma Death Rate by State, 1999-2015
Pleural Mesothelioma Survival Rates by Stage at Diagnosis
Doctors sort mesothelioma cases into stages to describe how far the cancer has spread. The mesothelioma stage at diagnosis affects the patient’s treatment options and prognosis.
|Mesothelioma Stage||Median Survival Time|
|Stage 1||22.2 months|
|Stage 2||20 months|
|Stage 3||17.9 months|
|Stage 4||14.9 months|
Source: Journal of Thoracic Oncology, 2016
The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program tracks 5-year relative survival rates for pleural mesothelioma by three groups: Localized, regional and distant stages.
|SEER Stage||5-Year Survival Rate|
|All SEER Stages||9%|
Source: SEER; 2008 and 2014
Demographic Factors in Mesothelioma Survival Rates
Research shows survival among women diagnosed with pleural mesothelioma is three times higher than survival for men. One 2014 study reported 13.4% of women survive for five years after treatment, compared to only 4.5% of men.
The one-year survival rate is about the same for all races. From three years on, survival is slightly worse for whites.
5-Year Mesothelioma Survival by Race
Overall, younger mesothelioma patients have a significantly higher survival rate than older patients. More than 50% of patients diagnosed before the age of 50 survive one year, while less than 33% of those 75 or older survive the same length of time.
Get Free Help Finding a Mesothelioma Specialist
Connect to a top specialist who understands your diagnosis and can recommend treatment options.Find a Doctor Near You
Where Does Mesothelioma Occur?
Mesothelioma Survival Rates by Site
Medical advances have made peritoneal mesothelioma easier to treat than pleural mesothelioma. A 2015 study from Translational Oncology reveals a large difference in survival rates.
Symptoms by Site
Mesothelioma symptoms vary depending on where the cancer forms. Mesothelioma can be challenging to diagnose because early-stage symptoms are usually mild or nonexistent.
|Abdominal Swelling or Tenderness|
|Loss of Appetite|
|Couging up Blood|
|Feeling of Fullness|
|Lumps Under Abdominal Skin|
|Lumps Under Skin of the Chest|
|Pressure on the Heart|
|Reduced Chest Expansion|
|Shortness of Breath|
Benefits from Cancer Treatment
Mesothelioma treatment may involve surgery, chemotherapy and radiation therapy. Patients can also enroll in clinical trials to try experimental treatments such as immunotherapy.
Key Stats About Mesothelioma Treatment
- More than 80% of patients receive chemotherapy, the most common treatment for mesothelioma.
- A 2016 study compiling SEER data showed chemotherapy tripled the survival rate of patients diagnosed with pleural or peritoneal mesothelioma.
- Less than 20% of pleural mesothelioma patients qualify for aggressive tumor-removing surgery.
- Half of peritoneal mesothelioma patients who receive HIPEC surgery live longer than five years.
Research has shown improved survival with multimodal therapy, an approach that combines two or more treatments.
A 2018 study presented at the eighth annual European Lung Cancer Congress showed a combination of surgery, chemotherapy and radiation produced an impressive one-year survival rate of 79.6% for pleural mesothelioma patients.
Combining surgery with chemotherapy is also effective for peritoneal mesothelioma. A 2018 International Journal of Hyperthermia study showed median disease-free survival was almost five years for peritoneal patients receiving HIPEC surgery, which combines cytoreductive surgery with heated chemotherapy. The median overall survival for patients in the study was more than eight years.
Only about 20% of pleural mesothelioma patients are eligible for aggressive tumor-removing surgery. For the rest, doctors are testing experimental drug regimens, including immunotherapy drugs already used in lung cancer treatment.
Immunotherapy Drugs Being Tested for Mesothelioma
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Ipilimumab (Yervoy)
- WT1 Vaccine
Human studies, called clinical trials, give patients access to the latest breakthroughs in treatment. Researchers have conducted more than 300 clinical trials for mesothelioma worldwide.
Mesothelioma Costs and Compensation
The National Cancer Institute statistics estimate the cost of lung cancer treatment at more than $60,000 for the first year. Mesothelioma treatment costs are comparable.
The RAND Corporation estimated the median value for mesothelioma claims as $180,000 in a 2010 research report. A 2019 analysis from consulting firm KCIC shows 2,087 mesothelioma lawsuits were filed in 2018.
Trusts: $30 Billion
In 2016, the RAND Corporation’s Institute for Civil Justice reported asbestos bankruptcy trusts hold a combined total of more than $30 billion. These trusts have paid claimants roughly $20 billion since the late 1980s.
15 Cited Article Sources
American Cancer Society. (2019, March 6). Survival Rates for Mesothelioma.
Retrieved from: https://www.cancer.org/cancer/malignant-mesothelioma/detection-diagnosis-staging/survival-statistics.html
American Cancer Society. (2019, January 9). Survival Rates for Mesothelioma.
Retrieved from: https://www.cancer.org/cancer/malignant-mesothelioma/about/key-statistics.html
Cancer.net. (2019, January). Mesothelioma: Statistics.
Retrieved from: https://www.cancer.net/cancer-types/mesothelioma/statistics
KCIC. (2019). Asbestos Litigation: 2018 Year In Review.
Retrieved from: https://www.kcic.com/media/1918/kcic-2018-asbestos-report.pdf
Powers, J. (2018, April 17). Analysis Supports Combination Therapy in Patients With Malignant Pleural Mesothelioma: Presented at ELCC.
Retrieved from: https://www.firstwordpharma.com/node/1557746
Powers, J. (2018, April 13). Endoglin Levels Signal Nintedanib Response in Patients With Malignant Pleural Mesothelioma: Presented at ELCC.
Retrieved from: https://www.firstwordpharma.com/node/1556853?tsid=17
Mazurek, J. et al. (2017, March 3). Malignant Mesothelioma Mortality — United States, 1999-2015.
Retrieved from: https://www.cdc.gov/mmwr/volumes/66/wr/mm6608a3.htm#T1_down
Beebe-Dimmer, J. et al. (2016, October 26). Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival.
Retrieved from: https://www.dovepress.com/mesothelioma-in-the-united-states-a-surveillance-epidemiology-and-end--peer-reviewed-fulltext-article-CLEP
Henley, S. et al. (2015, April 22). Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008.
Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406225/
Taioli, E. et al. (2014, September). Women with malignant pleural mesothelioma have a threefold better survival rate than men.
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/24928677
National Cancer Institute. (2011, January). Annualized Mean Net Costs of Care per Patient.
Retrieved from: https://costprojections.cancer.gov/annual.costs.html
Dixon, L., McGovern, G. & Coombe, A. (2010). Asbestos Bankruptcy Trusts: An Overview of Trust Structure and Activity with Detailed Reports on the Largest Trusts.
Retrieved from: http://www.rand.org/content/dam/rand/pubs/technical_reports/2010/RAND_TR872.pdf
Surveillance, Epidemiology, and End Results Program. (n.d.). Age-Adjusted SEER Cancer Incidence Rates, 1980-2015.
Retrieved from: https://seer.cancer.gov/archive/csr/1975_2015/browse_csr.php?sectionSEL=17&pageSEL=sect_17_table.01
Surveillance, Epidemiology, and End Results Program. (n.d.). Age-Adjusted Rates and Trends by Race/Ethnicity and Sex.
Retrieved from: https://seer.cancer.gov/archive/csr/1975_2015/browse_csr.php?sectionSEL=17&pageSEL=sect_17_table.11
- Surveillance, Epidemiology, and End Results Program. (n.d.). Mesothelioma 5-Year Relative and Period Survival by Race, Sex, Diagnosis Year and Age. Retrieved from: https://seer.cancer.gov/archive/csr/1975_2015/browse_csr.php?sectionSEL=17&pageSEL=sect_17_table.04
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified September 12, 2019